Publications

April 2012 (Revised May 2012)
Case

Merck: Operating Science-Based Business

By: Ananth Raman, Inga Maurer and William Schmidt

Merck is known for its commitment to investing in basic R&D. Are Merck's long-term investments justifiable when the firm faces extreme earnings pressure? View Details

Keywords: Science-Based Business; Management; Research and Development; Business and Shareholder Relations; Operations; Pharmaceutical Industry; United States

November 1991 (Revised August 2005)
Case

Whelan Pharmaceuticals: Tax Factors and Global Site Selection

Whelan Pharmaceuticals, a U.S. company with $3 billion in sales, must decide where to manufacture its newest product. In considering possible sites, both foreign and U.S., the firm must identify and make trade-offs between tax, marketing, and manufacturing factors. View Details

Keywords: Globalized Firms and Management; Geographic Location; Cost vs Benefits; Production; Pharmaceutical Industry; United States

October 2010 (Revised August 2016)
Case

On Weldon's Watch: Recalls at Johnson & Johnson from 2009 to 2010

By: Clayton S. Rose, Sandra J. Sucher, Rachel Gordon and Matthew Preble

In October of 2010, Johnson & Johnson (J&J) was unable to extricate itself from a year long recall crisis that had subjected the firm to criticism from Congress and regulators, resulted in the resignation of one of the firm's most senior officers, and cost hundreds of... View Details

Keywords: Decision Choices and Conditions; Values and Beliefs; Leadership; Crisis Management; Corporate Social Responsibility and Impact; Organizational Change and Adaptation; Organizational Culture; Quality; Pharmaceutical Industry

February 2010
Supplement

Organization and Strategy at Millennium (B)

By: Julie M. Wulf and Scott Waggoner

This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder CEO Mark... View Details

Keywords: Leading Change; Transformation; Decision Choices and Conditions; Crisis Management; Competitive Advantage; Commercialization; Selection and Staffing; Product Development; Organizational Change and Adaptation; Pharmaceutical Industry

June 2009 (Revised April 2017)
Teaching Note

Merck: Managing Vioxx (A)-(G)

By: Robert Simons and Natalie Kindred

Teaching Note for [109080], [109081], [109082], [109083], [109084], [109085], and [109086]. View Details

Keywords: Management Control Systems; Strategy And Execution; Crisis Management; Risk; Core Values; Pharmaceutical Industry

April 2009
Supplement

Merck: Managing Vioxx (E)

By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred

Keywords: Leadership; Decision Choices and Conditions; Customer Focus and Relationships; Pharmaceutical Industry

1999
Chapter

The Economics of Drug Discovery

By: Rebecca M. Henderson and Iain Cockburn

Keywords: Economics; Innovation and Invention; Research and Development; Pharmaceutical Industry

Read Now

August 2008 (Revised May 2009)
Background Note

Note on Generic Drugs in the European Union

By: Robert C. Pozen and Elizabeth M. Leonard

Rules governing the introduction of generic drugs in U.S. and EU have some similarities but significant differences because of the Hatch-Waxman Act in the U.S. View Details

Keywords: Governing Rules, Regulations, and Reforms; Government Legislation; Health Care and Treatment; Trademarks; Brands and Branding; Pharmaceutical Industry; European Union; United States

July 2008 (Revised September 2008)
Case

Recent Developments in the Ranbaxy Case

By: Robert C. Pozen

This brief case describes settlements Indian drug maker Ranbaxy has made with Pfizer and AstraZeneca, as well as Daiichi Kangyo's purchase of a majority shareholding in Ranbaxy in 2008. View Details

Keywords: Mergers and Acquisitions; Patents; Lawsuits and Litigation; Ownership Stake; Pharmaceutical Industry; India

September 2006
Teaching Note

Corporate Venture Capital at Eli Lilly (TN)

By: Richard G. Hamermesh and Erin Seefeld

Keywords: Venture Capital; Pharmaceutical Industry

September 2005 (Revised June 2006)
Case

WuXi PharmaTech

By: Richard G. Hamermesh and Simin Zhou

WuXi Pharmatech has gone from zero to $21 million in sales in three years. The company must decide its growth strategy and how best to finance and organize for rapid growth. View Details

Keywords: Growth Management; Capital Markets; Problems and Challenges; Pharmaceutical Industry; China

March 1989 (Revised August 1989)
Case

GI Wars: Tums vs. Rolaids—Positioning Over-the-Counter Drugs

By: Regina E. Herzlinger

Keywords: Health; Product Positioning; Pharmaceutical Industry

June 2004
Case

Aventis SA (B): A Company is Born

By: Joshua D. Margolis and Carin-Isabel Knoop

Supplements the (A) case. View Details

Keywords: Problems and Challenges; Mergers and Acquisitions; Horizontal Integration; Organizational Design; Organizational Culture; Pharmaceutical Industry; United States

April 2002
Article

A Tale of Two Experts: Thalidomide and Political Engagement in the United States and West Germany

By: Arthur A. Daemmrich

Keywords: Health; Government and Politics; Pharmaceutical Industry; United States; Germany

June 2003
Teaching Note

Discovering the Future: R&D Strategy at Merck (TN)

By: Gary P. Pisano

Teaching Note for (9-601-086). View Details

Keywords: Pharmaceutical Industry

October 2002 (Revised June 2003)
Background Note

New Frontiers in Target Discovery and Validation

By: Regina E. Herzlinger, Niv Caviar, Jon Chatterton and Andrea Lynn

Explains Immusol and Novartis's technology. View Details

Keywords: Information Technology; Technological Innovation; Pharmaceutical Industry

August 2001
Case

Scios, Inc.

By: Regina E. Herzlinger

Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process. View Details

Keywords: Governing Rules, Regulations, and Reforms; Health Care and Treatment; Cost Management; Cost vs Benefits; Social Issues; Pharmaceutical Industry; United States